CONVINCING evidence is now available to indicate that aureomycin and chloramphenicol are effective in suppressing the acute manifestations of brucellosis.1 Substantial numbers of patients have had prompt clinical remissions of the acute illness following treatment with both these agents. Despite improvement in treatment of the acute infection, however, there remains a serious therapeutic problem in the occurrence of an appreciable number of relapses. In the several series reported, including those described by us, the rate of relapse has ranged from less than one fourth to approximately one half of the total patients treated. Among the many factors which may influence the relapse rate is one common to virtually all the aforementioned studies, namely, a limitation of the total length of antimicrobial therapy to a period of about two weeks or less. In these various studies the regimens of therapy were principally determined by the amount of drug available, and
KNIGHT V, SANCHEZ FR, SANCHEZ AR. TERRAMYCIN IN TREATMENT OF HUMAN BRUCELLOSIS. AMA Arch Intern Med. 1951;87(6):835–843. doi:10.1001/archinte.1951.03810060064007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: